Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I. / Bratteby, Klas; Denholt, Charlotte Lund; Lehel, Szabolcs; Petersen, Ida Nymann; Madsen, Jacob; Erlandsson, Maria; Ohlsson, Tomas; Herth, Matthias Manfred; Gillings, Nic.

In: Pharmaceuticals, Vol. 14, No. 7, 601, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bratteby, K, Denholt, CL, Lehel, S, Petersen, IN, Madsen, J, Erlandsson, M, Ohlsson, T, Herth, MM & Gillings, N 2021, 'Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I', Pharmaceuticals, vol. 14, no. 7, 601. https://doi.org/10.3390/ph14070601

APA

Bratteby, K., Denholt, C. L., Lehel, S., Petersen, I. N., Madsen, J., Erlandsson, M., Ohlsson, T., Herth, M. M., & Gillings, N. (2021). Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I. Pharmaceuticals, 14(7), [601]. https://doi.org/10.3390/ph14070601

Vancouver

Bratteby K, Denholt CL, Lehel S, Petersen IN, Madsen J, Erlandsson M et al. Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I. Pharmaceuticals. 2021;14(7). 601. https://doi.org/10.3390/ph14070601

Author

Bratteby, Klas ; Denholt, Charlotte Lund ; Lehel, Szabolcs ; Petersen, Ida Nymann ; Madsen, Jacob ; Erlandsson, Maria ; Ohlsson, Tomas ; Herth, Matthias Manfred ; Gillings, Nic. / Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I. In: Pharmaceuticals. 2021 ; Vol. 14, No. 7.

Bibtex

@article{80a3277df0044d028350e64fef3607c5,
title = "Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I",
abstract = "In the struggle to understand and accurately diagnose Parkinson's disease, radiopharmaceuticals and medical imaging techniques have played a major role. By being able to image and quantify the dopamine transporter density, noninvasive diagnostic imaging has become the gold standard. In the shift from the first generation of SPECT tracers, the fluorine-18-labeled tracer [18F]FE-PE2I has emerged as the agent of choice for many physicians. However, implementing suitable synthesis for the production of [18F]FE-PE2I has proved more challenging than expected. Through a thorough analysis of the relevant factors affecting the final radiochemical yield, we were able to implement high-yielding fully automated GMP-compliant synthesis of [18F]FE-PE2I on a Synthera{\textregistered}+ platform. By reaching RCYs up to 62%, it allowed us to isolate 25 GBq of the formulated product, and an optimized formulation resulted in the shelf life of 6 h, satisfying the increased demand for this radiopharmaceutical.",
author = "Klas Bratteby and Denholt, {Charlotte Lund} and Szabolcs Lehel and Petersen, {Ida Nymann} and Jacob Madsen and Maria Erlandsson and Tomas Ohlsson and Herth, {Matthias Manfred} and Nic Gillings",
year = "2021",
doi = "10.3390/ph14070601",
language = "English",
volume = "14",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "M D P I AG",
number = "7",

}

RIS

TY - JOUR

T1 - Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I

AU - Bratteby, Klas

AU - Denholt, Charlotte Lund

AU - Lehel, Szabolcs

AU - Petersen, Ida Nymann

AU - Madsen, Jacob

AU - Erlandsson, Maria

AU - Ohlsson, Tomas

AU - Herth, Matthias Manfred

AU - Gillings, Nic

PY - 2021

Y1 - 2021

N2 - In the struggle to understand and accurately diagnose Parkinson's disease, radiopharmaceuticals and medical imaging techniques have played a major role. By being able to image and quantify the dopamine transporter density, noninvasive diagnostic imaging has become the gold standard. In the shift from the first generation of SPECT tracers, the fluorine-18-labeled tracer [18F]FE-PE2I has emerged as the agent of choice for many physicians. However, implementing suitable synthesis for the production of [18F]FE-PE2I has proved more challenging than expected. Through a thorough analysis of the relevant factors affecting the final radiochemical yield, we were able to implement high-yielding fully automated GMP-compliant synthesis of [18F]FE-PE2I on a Synthera®+ platform. By reaching RCYs up to 62%, it allowed us to isolate 25 GBq of the formulated product, and an optimized formulation resulted in the shelf life of 6 h, satisfying the increased demand for this radiopharmaceutical.

AB - In the struggle to understand and accurately diagnose Parkinson's disease, radiopharmaceuticals and medical imaging techniques have played a major role. By being able to image and quantify the dopamine transporter density, noninvasive diagnostic imaging has become the gold standard. In the shift from the first generation of SPECT tracers, the fluorine-18-labeled tracer [18F]FE-PE2I has emerged as the agent of choice for many physicians. However, implementing suitable synthesis for the production of [18F]FE-PE2I has proved more challenging than expected. Through a thorough analysis of the relevant factors affecting the final radiochemical yield, we were able to implement high-yielding fully automated GMP-compliant synthesis of [18F]FE-PE2I on a Synthera®+ platform. By reaching RCYs up to 62%, it allowed us to isolate 25 GBq of the formulated product, and an optimized formulation resulted in the shelf life of 6 h, satisfying the increased demand for this radiopharmaceutical.

U2 - 10.3390/ph14070601

DO - 10.3390/ph14070601

M3 - Journal article

C2 - 34206688

VL - 14

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 7

M1 - 601

ER -

ID: 282314516